伊扎莫布
多发性骨髓瘤
无进展生存期
耐火材料(行星科学)
医学
来那度胺
肿瘤科
内科学
泊马度胺
总体生存率
Carfilzomib公司
生物
天体生物学
作者
Hervé Avet‐Loiseau,Nizar J. Bahlis,Wee Joo Chng,Tamás Masszi,Luísa Viterbo,Luděk Pour,Peter Ganly,Antonio Palumbo,Michèle Cavo,Christian Langer,Andrzej Pluta,Arnon Nagler,Shaji Kumar,Dina Ben‐Yehuda,S. Vincent Rajkumar,Jesús F. San Miguel,Deborah Berg,Jianchang Lin,Helgi van de Velde,Dixie‐Lee Esseltine
出处
期刊:Blood
[Elsevier BV]
日期:2017-10-20
卷期号:130 (24): 2610-2618
被引量:111
标识
DOI:10.1182/blood-2017-06-791228
摘要
Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.
科研通智能强力驱动
Strongly Powered by AbleSci AI